US Patent Issued to Alnylam Pharmaceuticals on Jan. 13 for "Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof" (Massachusetts Inventors)

ALEXANDRIA, Va., Jan. 13 -- United States Patent no. 12,522,822, issued on Jan. 13, was assigned to Alnylam Pharmaceuticals Inc. (Cambridge, Mass.).

"Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof" was invented by Frederic Tremblay (Boston), Lucas D. BonDurant (Brookline, Mass.), James D. McIninch (Burlington, Mass.), Adam Castoreno (Framingham, Mass.), Mark K. Schlegel (Boston) and Charalambos Kaittanis (Cambridge, Mass.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the apolipoprotein C3 gene (APOC3). The invention also relates to methods of using such RNAi agents to inhibit expression ...